IL304014A - Indazole compounds as kinase inhibitors - Google Patents
Indazole compounds as kinase inhibitorsInfo
- Publication number
- IL304014A IL304014A IL304014A IL30401423A IL304014A IL 304014 A IL304014 A IL 304014A IL 304014 A IL304014 A IL 304014A IL 30401423 A IL30401423 A IL 30401423A IL 304014 A IL304014 A IL 304014A
- Authority
- IL
- Israel
- Prior art keywords
- compound according
- ring
- optionally substituted
- c6alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132031P | 2020-12-30 | 2020-12-30 | |
| US202163216879P | 2021-06-30 | 2021-06-30 | |
| PCT/US2021/065679 WO2022147246A1 (en) | 2020-12-30 | 2021-12-30 | Indazole compounds as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304014A true IL304014A (en) | 2023-08-01 |
Family
ID=80168316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304014A IL304014A (en) | 2020-12-30 | 2021-12-30 | Indazole compounds as kinase inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12264149B2 (https=) |
| EP (1) | EP4271673A1 (https=) |
| JP (2) | JP7791196B2 (https=) |
| KR (1) | KR20230152654A (https=) |
| AU (1) | AU2021411587B2 (https=) |
| CA (1) | CA3205986A1 (https=) |
| CL (1) | CL2023001951A1 (https=) |
| CO (1) | CO2023008689A2 (https=) |
| CR (1) | CR20230325A (https=) |
| EC (1) | ECSP23048136A (https=) |
| IL (1) | IL304014A (https=) |
| MX (1) | MX2023007793A (https=) |
| PE (1) | PE20240687A1 (https=) |
| WO (1) | WO2022147246A1 (https=) |
| ZA (1) | ZA202306559B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
| IL317558A (en) * | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| TW202408493A (zh) * | 2022-06-29 | 2024-03-01 | 美商泰拉生物科學公司 | 多晶形化合物及其用途 |
| AU2023334178A1 (en) | 2022-08-30 | 2025-03-13 | Tyra Biosciences, Inc. | Methods of treating solid tumors having activating fgfr3 gene alterations |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| WO2024138112A1 (en) * | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| JP2026500784A (ja) * | 2022-12-30 | 2026-01-08 | 江▲蘇▼▲亞▼虹医▲薬▼科技股▲フン▼有限公司 | ピラゾール縮合環化合物、並びにその調製方法及びその使用 |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN119306723B (zh) * | 2023-07-13 | 2026-04-10 | 长春金赛药业有限责任公司 | 吲唑类fgfr2/3选择性抑制剂、药物组合物及其应用 |
| WO2025021033A1 (zh) * | 2023-07-21 | 2025-01-30 | 长春金赛药业有限责任公司 | 成纤维细胞生长因子受体抑制剂、药物组合物及其应用 |
| WO2025021997A1 (en) | 2023-07-27 | 2025-01-30 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | New map4k1 inhibitors |
| WO2025061029A1 (en) * | 2023-09-18 | 2025-03-27 | 3H Pharmaceuticals Co., Ltd. | Fgfr inhibitors and methods of use thereof |
| WO2025064744A1 (en) | 2023-09-22 | 2025-03-27 | Tyra Biosciences, Inc. | Tyra-300 (5-[(1r)-1-(3,5-dichloro-4-pyridyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-1h-indazole ) in combination with a pd-1 or pd-l1 antagonist for use in the treatment of cancer |
| TW202535368A (zh) * | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025170959A1 (en) | 2024-02-05 | 2025-08-14 | Tyra Biosciences, Inc. | Combination of the fgfr 3 inhibitor tyra-300 and a nectin-4 targeting agent-drug conjugate for use in the treatment of cancer |
| WO2025199217A1 (en) | 2024-03-19 | 2025-09-25 | Tyra Biosciences, Inc. | Pharmaceutical compositions |
| WO2026020109A1 (en) * | 2024-07-19 | 2026-01-22 | Tyra Biosciences, Inc. | Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer |
| WO2026035809A1 (en) * | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB8808433D0 (en) | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5041453A (en) | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
| US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| WO1997036876A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL135900A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeuticaly active compounds |
| IL135714A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CN1300116C (zh) | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h－吲唑化合物 |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| CA2542220A1 (en) | 2003-10-22 | 2005-05-06 | Eli Lilly And Company | Novel mch receptor antagonists |
| WO2005060958A1 (en) | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006096564A1 (en) | 2005-03-04 | 2006-09-14 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| WO2008008650A1 (en) | 2006-07-10 | 2008-01-17 | Indiana University Research And Technology Corporation | Methods for treating cystic kidney diseases |
| SG177225A1 (en) | 2006-12-01 | 2012-01-30 | Agency Science Tech & Res | Cancer-related protein kinases |
| MX2009008439A (es) | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
| JP5330375B2 (ja) | 2007-04-25 | 2013-10-30 | エグゼリクシス， インコーポレイテッド | カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピリミジノン類 |
| AU2008248186B2 (en) | 2007-05-07 | 2014-02-06 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| CA2750577A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| EP2379563B1 (en) | 2008-12-22 | 2014-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| EP2368876A1 (en) | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
| US20130079348A1 (en) | 2010-03-03 | 2013-03-28 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP5763937B2 (ja) | 2010-03-10 | 2015-08-12 | Ａｇｃセイミケミカル株式会社 | 液晶化合物、その製造方法、液晶組成物および液晶電気光学素子 |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| JO3062B1 (ar) | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2012092471A2 (en) | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| CN102243505B (zh) | 2011-07-07 | 2013-08-14 | 矽力杰半导体技术(杭州)有限公司 | 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路 |
| US9267176B2 (en) | 2011-08-05 | 2016-02-23 | Astellas Pharma Inc. | Method for detecting novel FGFR4 mutant |
| JP2014525932A (ja) | 2011-08-15 | 2014-10-02 | インターミューン， インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
| JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
| CN108484449A (zh) | 2011-09-09 | 2018-09-04 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| CN103420906B (zh) | 2012-05-21 | 2015-09-09 | 南京圣和药业股份有限公司 | 新型酪氨酸蛋白激酶抑制剂 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| KR101648141B1 (ko) | 2013-06-11 | 2016-08-12 | 제일모직 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치 |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| WO2015035415A1 (en) | 2013-09-09 | 2015-03-12 | Nantomics, Llc | Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US9546162B2 (en) | 2013-09-27 | 2017-01-17 | Allergan, Inc. | Compounds and methods for skin repair |
| US9931347B2 (en) | 2013-12-03 | 2018-04-03 | Iomet Pharma Ltd. | Pharmaceutical compound |
| US10767222B2 (en) | 2013-12-11 | 2020-09-08 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| JP6514645B2 (ja) | 2013-12-27 | 2019-05-15 | 中外製薬株式会社 | Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬 |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| US20160340742A1 (en) | 2014-02-04 | 2016-11-24 | Mayo Foundation For Medical Education And Research | Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients |
| CN106459993A (zh) | 2014-03-31 | 2017-02-22 | 德彪药业国际股份公司 | Fgfr融合体 |
| WO2015154169A1 (en) | 2014-04-09 | 2015-10-15 | The University Of British Columbia | Binding function3 (bf3) site compounds as therapeutics and methods for their use |
| KR102352667B1 (ko) | 2014-05-09 | 2022-01-19 | 메르크 파텐트 게엠베하 | 액정 매질 및 이를 포함하는 고주파 부품 |
| CA2949511A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| US20170281642A1 (en) | 2014-08-28 | 2017-10-05 | Oncoethix Gmbh | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
| JP2017535646A (ja) | 2014-11-11 | 2017-11-30 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ | ビメソゲン化合物及びメソゲン媒体 |
| JP2018027019A (ja) | 2014-11-26 | 2018-02-22 | 国立研究開発法人国立がん研究センター | 胆道がんにおける新規治療標的融合遺伝子 |
| WO2016105503A1 (en) | 2014-12-24 | 2016-06-30 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| EP3265462A1 (en) | 2015-03-03 | 2018-01-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fgfr3 antagonists |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| CN106317023A (zh) | 2015-07-10 | 2017-01-11 | 中国科学院上海药物研究所 | 吲唑类化合物的制备方法和用途 |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| WO2017068064A1 (en) | 2015-10-22 | 2017-04-27 | Selvita S.A. | Pyridone derivatives and their use as kinase inhibitors |
| JPWO2017150586A1 (ja) | 2016-03-02 | 2019-01-31 | Jnc株式会社 | 積層体、電子機器、積層体の製造方法 |
| JP6959488B2 (ja) | 2016-03-02 | 2021-11-02 | Jnc株式会社 | 低熱膨張部材用組成物、低熱膨張部材、電子機器、低熱膨張部材の製造方法 |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| US20190177617A1 (en) | 2016-05-12 | 2019-06-13 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
| US11124628B2 (en) | 2016-08-30 | 2021-09-21 | Dow Global Technologies Llc | Method of attenuating concerntration of acrolein |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| WO2019018795A1 (en) | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| EP3669872A4 (en) | 2017-08-18 | 2021-05-05 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF |
| US11795162B2 (en) | 2017-08-18 | 2023-10-24 | Saint Louis University | Modulators of the estrogen-related receptor |
| WO2019209948A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| KR102127006B1 (ko) | 2018-12-06 | 2020-06-25 | 한국생산기술연구원 | 피리미딘계 작용기 함유 단분자 화합물, 상기 화합물의 광가교물을 포함한 유기물층 및 이를 포함하는 유기전자소자 |
| WO2020139748A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| IN201941011265A (https=) * | 2019-03-22 | 2020-09-25 | ||
| EP3971187B1 (en) | 2019-05-14 | 2025-05-07 | Shanghai Hansoh Biomedical Co., Ltd. | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112812014B (zh) | 2019-11-15 | 2024-05-10 | 石家庄诚志永华显示材料有限公司 | 化合物、液晶组合物、液晶显示器 |
| TW202128670A (zh) | 2019-11-26 | 2021-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮多環類衍生物抑制劑、其製備方法和應用 |
| WO2021127333A1 (en) | 2019-12-19 | 2021-06-24 | Casma Therapeutics, Inc. | Trpml modulators |
| US12441707B2 (en) * | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021155253A1 (en) | 2020-01-31 | 2021-08-05 | Atomwise Inc. | Anat inhibitors and methods of use thereof |
| CA3166358A1 (en) | 2020-02-12 | 2021-08-19 | Monali BANERJEE | Small molecule sting antagonists |
| US20230148214A1 (en) | 2020-03-06 | 2023-05-11 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| BR112022022511A2 (pt) | 2020-05-06 | 2022-12-13 | Servier Lab | Inibidores macrocíclicos de lrrk2 quinase |
| KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
| BR112023017834A2 (pt) | 2021-03-18 | 2023-10-03 | Servier Lab | Inibidores de lrrk2 cinase macrocíclicos |
| JP2024512501A (ja) | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| US20240316022A1 (en) * | 2021-06-30 | 2024-09-26 | Tyra Biosciences, Inc. | Indazole compounds |
| KR20240171138A (ko) | 2022-04-04 | 2024-12-06 | 브레닉 테라퓨틱스 인코포레이티드 | Lrrk2 저해제 |
| TW202408493A (zh) | 2022-06-29 | 2024-03-01 | 美商泰拉生物科學公司 | 多晶形化合物及其用途 |
| IL317558A (en) | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| AU2023334178A1 (en) | 2022-08-30 | 2025-03-13 | Tyra Biosciences, Inc. | Methods of treating solid tumors having activating fgfr3 gene alterations |
-
2021
- 2021-12-30 KR KR1020237024903A patent/KR20230152654A/ko active Pending
- 2021-12-30 US US18/259,422 patent/US12264149B2/en active Active
- 2021-12-30 AU AU2021411587A patent/AU2021411587B2/en active Active
- 2021-12-30 JP JP2023540770A patent/JP7791196B2/ja active Active
- 2021-12-30 WO PCT/US2021/065679 patent/WO2022147246A1/en not_active Ceased
- 2021-12-30 IL IL304014A patent/IL304014A/en unknown
- 2021-12-30 CR CR20230325A patent/CR20230325A/es unknown
- 2021-12-30 CA CA3205986A patent/CA3205986A1/en active Pending
- 2021-12-30 MX MX2023007793A patent/MX2023007793A/es unknown
- 2021-12-30 PE PE2023001961A patent/PE20240687A1/es unknown
- 2021-12-30 EP EP21852113.6A patent/EP4271673A1/en active Pending
-
2023
- 2023-06-26 ZA ZA2023/06559A patent/ZA202306559B/en unknown
- 2023-06-26 EC ECSENADI202348136A patent/ECSP23048136A/es unknown
- 2023-06-30 CO CONC2023/0008689A patent/CO2023008689A2/es unknown
- 2023-06-30 CL CL2023001951A patent/CL2023001951A1/es unknown
-
2024
- 2024-02-22 US US18/584,440 patent/US12071428B2/en active Active
-
2025
- 2025-02-03 US US19/043,650 patent/US20250340533A1/en active Pending
- 2025-12-09 JP JP2025243767A patent/JP2026048777A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026048777A (ja) | 2026-03-17 |
| US12071428B2 (en) | 2024-08-27 |
| AU2021411587A1 (en) | 2023-07-06 |
| ZA202306559B (en) | 2025-09-25 |
| US20250340533A1 (en) | 2025-11-06 |
| US20240208941A1 (en) | 2024-06-27 |
| JP7791196B2 (ja) | 2025-12-23 |
| MX2023007793A (es) | 2023-09-22 |
| JP2024502433A (ja) | 2024-01-19 |
| US20240109865A1 (en) | 2024-04-04 |
| ECSP23048136A (es) | 2023-09-29 |
| CA3205986A1 (en) | 2022-07-07 |
| AU2021411587B2 (en) | 2024-10-10 |
| WO2022147246A1 (en) | 2022-07-07 |
| US12264149B2 (en) | 2025-04-01 |
| CL2023001951A1 (es) | 2023-12-01 |
| EP4271673A1 (en) | 2023-11-08 |
| CO2023008689A2 (es) | 2023-09-29 |
| CR20230325A (es) | 2023-12-11 |
| KR20230152654A (ko) | 2023-11-03 |
| PE20240687A1 (es) | 2024-04-10 |
| TW202241906A (zh) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304014A (en) | Indazole compounds as kinase inhibitors | |
| EP3322711B1 (en) | Hpk1 inhibitors and methods of using same | |
| RU2638116C2 (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
| TWI570117B (zh) | 吡唑－４－基－雜環甲醯胺化合物及使用方法 | |
| JP6242885B2 (ja) | ５−アザインダゾール化合物及び使用方法 | |
| AU2015320675B2 (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds | |
| WO2023279041A1 (en) | Indazole compounds | |
| US20250368666A1 (en) | Indazole compounds | |
| JP2022542072A (ja) | ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体 | |
| CN116761798A (zh) | 作为激酶抑制剂的吲唑类化合物 | |
| EA050408B1 (ru) | Соединение индазола в качестве ингибиторов киназы | |
| WO2026035809A1 (en) | Indazole compounds for the treatment of cancer | |
| CN117279908A (zh) | 用于治疗认知障碍的杂芳基化合物 | |
| CN121752567A (zh) | 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物 | |
| HK40100302A (zh) | 作为激酶抑制剂的吲唑类化合物 | |
| HK1233645A1 (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds | |
| HK1196125B (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| HK1196125A (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |